LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve

Authors

• Lori J Wirth
• Marcia S Brose
• Rossella Elisei
• Jaume Capdevila
• Ana O Hoff
• Mimi I Hu
• Makoto Tahara
• Bruce Robinson
• Ming Gao
• Meng Xia
• Patricia Maeda
• Eric Sherman

Publication/Presentation Date

9-1-2022

Abstract

Selpercatinib is a first-in-class, highly selective and potent, central nervous system-active

Volume

18

Issue

28

First Page

3143

Last Page

3150

ISSN

1744-8301

Published In/Presented At

Wirth, L. J., Brose, M. S., Elisei, R., Capdevila, J., Hoff, A. O., Hu, M. I., Tahara, M., Robinson, B., Gao, M., Xia, M., Maeda, P., & Sherman, E. (2022). LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer. Future oncology (London, England), 18(28), 3143–3150. https://doi.org/10.2217/fon-2022-0657

Disciplines

Medicine and Health Sciences

PubMedID

35969032

Department(s)

Hematology-Medical Oncology Division

Document Type

Article